X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Exscientia and the University of Oxford announce partnership to develop treatments for Alzheimer's disease

    Exscientia and the University of Oxford announce partnership to develop treatments for Alzheimer’s disease

    Fasenra shows consistent safety and sustained efficacy in long-term Phase III BORA trial in severe eosinophilic asthma

    AstraZeneca and IDT Biologika sign LOI to increase COVID-19 vaccine manufacturing in Europe and secure long-term supply capacity

    Astrazeneca Says Covid-19 Long-Acting Antibody Combination AZD7442 Rapidly Advances Into Phase III Clinical Trials

    Algernon Pharmaceuticals Considers Adding Lung Scarring as an Additional Endpoint for its Phase 2b/3 COVID-19 Study Protocol

    Samsung Biologics, National OncoVenture, and Eutilex obtains IND Approval from FDA

    Samsung Biologics, National OncoVenture, and Eutilex obtains IND Approval from FDA

    Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate

    Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate

    Gavi, the Vaccine Alliance, Collaborates with Salesforce to Help Equitably Distribute Two Billion COVID-19 Vaccines by the End of 2021

    GSK and CureVac to develop next generation mRNA COVID-19 vaccines

    Oxford leads first trial investigating dosing with alternating vaccines

    Oxford leads first trial investigating dosing with alternating vaccines

    Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines

    Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines

    Merck, Pfizer get EU nod for Bavencio as bladder cancer maintenance

    Merck, Pfizer get EU nod for Bavencio as bladder cancer maintenance

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Exscientia and the University of Oxford announce partnership to develop treatments for Alzheimer's disease

    Exscientia and the University of Oxford announce partnership to develop treatments for Alzheimer’s disease

    Fasenra shows consistent safety and sustained efficacy in long-term Phase III BORA trial in severe eosinophilic asthma

    AstraZeneca and IDT Biologika sign LOI to increase COVID-19 vaccine manufacturing in Europe and secure long-term supply capacity

    Astrazeneca Says Covid-19 Long-Acting Antibody Combination AZD7442 Rapidly Advances Into Phase III Clinical Trials

    Algernon Pharmaceuticals Considers Adding Lung Scarring as an Additional Endpoint for its Phase 2b/3 COVID-19 Study Protocol

    Samsung Biologics, National OncoVenture, and Eutilex obtains IND Approval from FDA

    Samsung Biologics, National OncoVenture, and Eutilex obtains IND Approval from FDA

    Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate

    Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate

    Gavi, the Vaccine Alliance, Collaborates with Salesforce to Help Equitably Distribute Two Billion COVID-19 Vaccines by the End of 2021

    GSK and CureVac to develop next generation mRNA COVID-19 vaccines

    Oxford leads first trial investigating dosing with alternating vaccines

    Oxford leads first trial investigating dosing with alternating vaccines

    Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines

    Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines

    Merck, Pfizer get EU nod for Bavencio as bladder cancer maintenance

    Merck, Pfizer get EU nod for Bavencio as bladder cancer maintenance

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

GSK to sell Cephalosporin antibiotics business to Sandoz

Content Team by Content Team
22nd February 2021
in News
The Falling Graph of Dose Contract Manufacturing

GSK has announced it has reached an agreement with Sandoz, a Novartis division, to sell its Cephalosporin antibiotics business. Sandoz will pay GSK USD 350 million at closing, plus additional milestone payments up to USD 150 million, subject to the terms of the transaction. The transaction is subject to relevant anti-trust and regulatory clearances and is expected to close in the second half of 2021.

The transaction aligns with GSK’s strategy to prioritise and simplify its portfolio and invest in the company’s innovative R&D pipeline and new product launches.

Cephalosporin manufacturing will transfer from GSK sites to Sandoz following a four-year manufacturing and supply agreement (MSA) and subsequent transfer of manufacturing operations. GSK proposes to close its Cephalosporins manufacturing operations once the transfer of manufacturing operations to Sandoz is complete and the MSA has come to an end, currently expected to be in 2025. GSK is providing support to potentially affected employees and is committed to supporting the local communities affected.

Cephalosporins are a well-established class of antibiotics used to treat a range of bacterial infections. The products being divested include the Zinnat, Zinacef and Fortum brands all of which are now off-patent. In 2020, the three brands had combined sales of approximately USD 140 million in the relevant markets.

The company has previously divested Fortum and Zinacef in the US and Germany and Fortum and Zinnat in Australia. The transaction includes all other markets except India, Pakistan, Egypt, Japan (relating to local Fortum brands) and China (excluding Taiwan, Hong Kong and Macau).

Other brands in GSK’s antibiotics portfolio, and GSK’s research and development into innovative antibiotics are not impacted by this divestment.

About GSK

GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.

Previous Post

Evonik strengthens strategic partnership with BioNTech on COVID-19 vaccine

Next Post

Thermo Fisher Scientific: New, online 2D-LC System empowers scientists to confidently characterize complex samples

Related Posts

MaxiVAX and Minaris Regenerative Medicine Enter into a Manufacturing Partnership for MVX-ONCO-2 Cancer Immunotherapy
News

MaxiVAX and Minaris Regenerative Medicine Enter into a Manufacturing Partnership for MVX-ONCO-2 Cancer Immunotherapy

22nd February 2021
online 2D-LC System empowers
News

Thermo Fisher Scientific: New, online 2D-LC System empowers scientists to confidently characterize complex samples

22nd February 2021
Johnson & Johnson Prepares to Resume Phase 3 ENSEMBLE Trial of its Janssen COVID-19 Vaccine Candidate in the U.S.
Manufacturing

Evonik strengthens strategic partnership with BioNTech on COVID-19 vaccine

14th February 2021
Qatar approves emergency use of Modernas COVID-19 vaccine
News

Qatar approves emergency use of Modernas COVID-19 vaccine

14th February 2021
Sepha launches small batch Contract Packaging Service
News

Sepha launches small batch Contract Packaging Service

14th February 2021
Exscientia and the University of Oxford announce partnership to develop treatments for Alzheimer's disease
Drug Development

Exscientia and the University of Oxford announce partnership to develop treatments for Alzheimer’s disease

14th February 2021
Next Post
online 2D-LC System empowers

Thermo Fisher Scientific: New, online 2D-LC System empowers scientists to confidently characterize complex samples

Latest News

MaxiVAX and Minaris Regenerative Medicine Enter into a Manufacturing Partnership for MVX-ONCO-2 Cancer Immunotherapy
News

MaxiVAX and Minaris Regenerative Medicine Enter into a Manufacturing Partnership for MVX-ONCO-2 Cancer Immunotherapy

22nd February 2021
online 2D-LC System empowers
News

Thermo Fisher Scientific: New, online 2D-LC System empowers scientists to confidently characterize complex samples

22nd February 2021
The Falling Graph of Dose Contract Manufacturing
News

GSK to sell Cephalosporin antibiotics business to Sandoz

22nd February 2021
Johnson & Johnson Prepares to Resume Phase 3 ENSEMBLE Trial of its Janssen COVID-19 Vaccine Candidate in the U.S.
Manufacturing

Evonik strengthens strategic partnership with BioNTech on COVID-19 vaccine

14th February 2021
Qatar approves emergency use of Modernas COVID-19 vaccine
News

Qatar approves emergency use of Modernas COVID-19 vaccine

14th February 2021
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In